1. Home
  2. TWG vs KALA Comparison

TWG vs KALA Comparison

Compare TWG & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TWG
  • KALA
  • Stock Information
  • Founded
  • TWG 2009
  • KALA 2009
  • Country
  • TWG Hong Kong
  • KALA United States
  • Employees
  • TWG N/A
  • KALA N/A
  • Industry
  • TWG
  • KALA Biotechnology: Pharmaceutical Preparations
  • Sector
  • TWG
  • KALA Health Care
  • Exchange
  • TWG NYSE
  • KALA Nasdaq
  • Market Cap
  • TWG 26.8M
  • KALA 32.0M
  • IPO Year
  • TWG 2024
  • KALA 2017
  • Fundamental
  • Price
  • TWG $0.28
  • KALA $6.77
  • Analyst Decision
  • TWG
  • KALA Strong Buy
  • Analyst Count
  • TWG 0
  • KALA 2
  • Target Price
  • TWG N/A
  • KALA $16.50
  • AVG Volume (30 Days)
  • TWG 16.3M
  • KALA 36.4K
  • Earning Date
  • TWG 11-22-2024
  • KALA 11-12-2024
  • Dividend Yield
  • TWG N/A
  • KALA N/A
  • EPS Growth
  • TWG 27.13
  • KALA N/A
  • EPS
  • TWG 0.09
  • KALA N/A
  • Revenue
  • TWG $16,943,287.00
  • KALA N/A
  • Revenue This Year
  • TWG N/A
  • KALA N/A
  • Revenue Next Year
  • TWG N/A
  • KALA N/A
  • P/E Ratio
  • TWG $3.28
  • KALA N/A
  • Revenue Growth
  • TWG 99.03
  • KALA N/A
  • 52 Week Low
  • TWG $0.17
  • KALA $4.21
  • 52 Week High
  • TWG $13.50
  • KALA $10.97
  • Technical
  • Relative Strength Index (RSI)
  • TWG N/A
  • KALA 53.32
  • Support Level
  • TWG N/A
  • KALA $6.65
  • Resistance Level
  • TWG N/A
  • KALA $7.85
  • Average True Range (ATR)
  • TWG 0.00
  • KALA 0.36
  • MACD
  • TWG 0.00
  • KALA -0.02
  • Stochastic Oscillator
  • TWG 0.00
  • KALA 7.43

About TWG TOP WEALTH GROUP HLDG LTD

Top Wealth Group Holding Ltd is as supplier of caviar and offer caviar-based gourmet products. It is specialized in supplying high quality sturgeons caviar.

About KALA KALA BIO Inc.

Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Share on Social Networks: